Cost-Effectiveness Analysis of Budesonide/Formoterol and Fluticasone/Salmeterol for Stable Chronic Obstructive Lung Disease

Amelia Lorensia,[1] Monica Dyah Puspitasari,[1] Soedarsono,[2] Rivan Virlando Suryadinata[3]

[1]*Department of Clinical-Community Pharmacy Faculty of Pharmacy, Universitas Surabaya, Surabaya, Indonesia*
[2]*Departement of Pulmonology and Respiratory Medicine Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia*
[3]*Department of Public Health Faculty of Medicine, Universitas Surabaya, Surabaya, Indonesia*

Abstract

Background: Chronic Obstructive Pulmonary Disease (COPD) is one of the four largest types of non-communicable diseases in the world, requiring long-term and routine treatment. Treatment with the inhalation route is in the form of a dry-powder inhaler (DPI) which is easy to use and carry. Combination of corticosteroid and long-acting beta-2 agonist (LABA) in the form of DPI available in Indonesia are budesonide/formoterol and salmeterol/fluticasone. The purpose was to identify therapy was more cost-effective between budesonide/formoterol than fluticasone/salmeterol in clinical symptoms using COPD assessment test (CAT) value and lung function in FEV_1/FVC (Forced Expiratory Volume in First Seconds/Forced Vital Capacity) ratio.

Methods: This research study was pre-post design with cost-effectiveness analysis, in outpatient COPD patients in a hospital in Gresik Regency, from October 2019 to January 2020. There were two outcomes of respondents in this study, namely lung function seen from the value of FEV_1, and clinical symptoms seen from the value of CAT. The study used hospital perspective.

Results: There were 38 respondents involved. Fluticasone/salmeterol therapy was more effective than the budesonide/formoterol group in improving FEV_1/FVC ratio, while budesonide/formoterol was more effective than the fluticasone/salmeterol group in improving clinical symptoms by CAT assessment. The average cost effectiveness ratio (ACER) value of lung function between the fluticasone/salmeterol group (IDR.176.465/Liter) was lower than that of budesonide/formoterol (IDR.296.832/Liter). The ACER clinical symptoms value between the fluticasone/salmeterol group (IDR.16,283/score) was smaller than that of budesonide/formoterol (IDR.17,340/score).

Conclusion: Fluticasone/salmeterol was more cost-effective than budesonide/formoterol in improving lung function. Meanwhile, for clinical symptoms, fluticasone/salmeterol was trade-off with budesonide/formoterol.

Keywords: COPD; FEV_1/FVC ratio; inhaled corticosteroid; Long-acting Beta-2 Agonist

INTRODUCTION

Chronic Obstructive Pulmonary Disease (COPD) is a disease characterized by airflow limitation that is not fully reversible. The airway limitation is usually progressive and is associated with an inflammatory response due to noxious substances or gases. COPD is one of the respiratory system diseases that is the cause of high morbidity and mortality in the world.[1] COPD comorbidities will result in cardiovascular disease, bronchial cancer, lung infections, thromboembolic disorders, the presence of asthma, hypertension, osteoporosis, joint pain, depression and anxiety.[2]

Respiratory diseases such as asthma and COPD require long-term and regular treatment. The route of drug administration is generally by inhalation because the effect is directly on the target organ in the lungs and causes side effects that tend to be smaller than other routes, because the drug works topically so it does not require larger doses as in systemic administration. One of the maintenance treatments for COPD is a combination of LABA and inhaled corticosteroid (ICS) in one package.[3]

Inhalers were an important drug delivery device in COPD because they enter the respiratory system directly and have fewer side effects.[4] The DPI type inhaler was relatively easier than MDI because

it does not require coordination between pressing and inhaling. Dry-powder inhaler (DPI) is in the form of a fine powder that acts directly on the respiratory tract of the bronchioles so that the effect of the drug can be faster and side effects that often appear in systemic treatment.[5] The combination of ICS and LABA in the form of DPI in Indonesia was combination of budesonide/formoterol and salmeterol/fluticasone.

The total direct cost of COPD diagnosis-treatment for each year from 2012 to 2016 in Turkey. The direct costs of the patients who were admitted to step 1, step 2, and step 3 health care centers between 2012 and 2016 increased by 41%; the increase was 60% and 24%, for inpatient and outpatient groups respectively. In the year 2016, the direct total cost was 1003TL ($332) per patient. For the inpatient group, the mean number of hospitalizations per patient, mean number of hospitalization days, and the mean cost per hospitalization were 0.4, 6.5, and 1926TL ($637), respectively.[6]

In Indonesia, a previous study on COPD inpatients at Sukoharjo General Hospital,[7] showed that the average cost of COPD for severe severity was IDR.1,349,671 for the three types of financing, for the very severe level, the types of general financing, JAMKESMAS (*Jaminan Kesehatan Masyarakat*/ Community Health insurance) and JAMKESDA (*Program Jaminan Kesehatan Masyarakat Daerah*/ Regional Public Health Insurance Program) were IDR.1,051,955.5, ID.1,815,859 and IDR. 1,589,706.5. The results showed that the average real cost of COPD treatment was lower and significantly different from the cost of the INA-CBG package. While the cost of outpatient treatment had not been found.

Based on the results of the above study, it was more directed to the cost of therapy in COPD patients, but not many studies had examined the effectiveness compared to the costs incurred by patients with COPD and family.[8,9] The implementation of these studies can give clinicians confidence in providing therapy rationally (effectively and efficiently) and reduce costs incurred by patients or their families.[10]

This method of cost-effectiveness analysis was the simplest, easiest and most applicable method in its application. The most appropriate pharmacoeconomic method for analysis was cost-effectiveness analysis (CEA) because of comparing therapeutic outcomes that can be measured in the same unit and costs are measured in currency.[11] CEA was most often used for economic analysis of health economics and is often used in drug therapy.[12] Outcomes of therapy in CEA can be investigated with the COPD Assessment Test (CAT) and spirometry.[13]

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends a multidimensional assessment called the Combined COPD assessment that combines the degree of obstruction or a history of acute exacerbations and an assessment of the patient's symptoms/impacts.[14] The spirometry classification assessment alone often does not represent the impact of COPD on the patient's quality of life.[15]

The quantitative assessment of symptoms, represented by the CAT, was aimed at evaluating the health impact on sufferers. This instrument has been validated in several European countries as well as the United States and has a good correlation with the more complex St George Respiratory Questionnaire (SGRQ). The CAT which has been translated into 61 languages and in Asia has been validated together, including in Indonesia. This test contains 8 questions with a score between 0–5 so that the total score will range between 0 and 40. The higher a person's score, the higher the impact of COPD on the patient's health status. Filling out the questionnaire in the CAT is done directly by the patient.[16]

Many parameters and methods are available for the purposes of assessing lung function. Impaired lung function can be tested using spirometry, the value used to detect the disorder is characterized by a decrease in Forced Vital Capacity (FVC) and Forced Expiratory Volume in First Seconds (FEV_1). Spirometry is an examination technique to determine lung function. The patient is asked to blow as hard as possible through a device that is connected to a spirometer machine which will automatically calculate the force, velocity and volume of air

expelled, so that the condition of the patient's lung function can be known.[17–19] The purpose of this study was to find out which therapy was more cost effective between budesonide/formoterol than fluticasone/salmeterol in terms of clinical symptoms using the CAT questionnaire and spirometry (FEV_1/FVC ratio).

METHODS

The research design was prospective observational study with pre-post design by conducting comparative study between budesonide/formoterol versus fluticasone/salmeterol in outpatient COPD patients in a hospital in Gresik Regency, from October 2019 to January 2020. The study used hospital perspective. And had received a certificate of ethics from the University of Surabaya No. 108/KE/XI/2019.

The effectiveness of budesonide/formoterol and fluticasone/salmeterol with FEV_1/FVC ratio, CAT questionnaire, and the incidence of drug side effects. Side effects were adverse drug reaction (ADR) and monitored for 3 months, namely oropharyngeal candidiasis (signs: white patches or plaques on the tongue and mucous membranes of the mouth) and pharyngitis (signs: sore throat, difficulty swallowing). The costs used were direct medical costs, including drugs, medical service, physical service, laboratory service, hospital service, and costs incurred to treat the side effects of COPD drugs that arise. The cost of health services listed on the patient's payment receipt.

The population was all patients who went to the pulmonary polyclinic of hospital X in Gresik between October 2019 and January 2020. The samples were all COPD patients who had used budesonide/formoterol or fluticasone/salmeterol therapy for 3 months, with age criteria >40 years, and willing to be involved in the research for 3 months. The sampling method was carried out using purposive sampling method.

The instruments used in the study were: CAT for the assessment of lung function. Consists of 8 questions with a score of 0-5 per question (Total scores ranged between 0 and 40). The greater a person's score, the higher the impact of COPD on the patient's health status. Assessment of lung function/physiology using spirometry, the value used to detect impaired lung function/physiology is marked by a decrease in FEV_1 and FVC.

Monitoring therapy for 3 months on the appearance of side effects of oropharyngeal candidiasis and pharyngitis with the Naranjo Scale. Pharmacoeconomic analysis by calculating ACER (Average Cost Effectiveness Ratio) by calculating the ratio of total cost to outcome, lung function (FEV_1/FVC ratio) and clinical symptoms (CAT). Then proceed with a different test to see the outcome, namely FEV_1/FVC ratio with t-test or Mann-Whitney test (ratio data scale) and CAT value with chi-square test (ordinal data scale).

RESULTS

The results of data collection on COPD patients receiving budesonide/formoterol and fluticasone/salmeterol therapy at the pulmonary polyclinic of X Hospital in Gresik from October 2019 to January 2020. There were 38 respondents involved in the study.

From Table 1, it can be seen that the characteristics of respondents based on gender, respondents were more male (52.63%) than female (47.37%). Characteristics of age, the largest number of respondents were 61-70 years old (50.00%). In terms of type of work, more respondents are not working or have retired. Most respondents are those who have quit smoking (52.63%). As for the characteristics of the incidence of drug side effects, neither side effects were found at all.

There were two outcomes of respondents in this study, namely lung function seen from the value of FEV_1 and clinical symptoms seen from the value of CAT which was shown in Table 2. Pulmonary function in both the budesonide/formoterol and fluticasone/salmeterol groups by looking at the FEV_1/FVC obtained $P=0.007$ explained that there was a significant difference between lung function in the two groups budesonide/formoterol and

fluticasone/salmeterol. Meanwhile, for clinical symptoms by looking at the patient's CAT score, P=0.880 explained that there was no significant difference between the clinical symptoms of budesonide/formoterol and fluticasone/salmeterol.

In this study, the effectiveness of treatment was assessed based on a comparison of lung function and COPD symptoms. The total FEV_1/FVC ratio in the fluticasone/salmeterol group (28.42 liters) was greater than in the budesonide/formoterol group (20.33 liters). The average FEV_1/FVC ratio in the fluticasone/salmeterol group (1.58 liters) was greater than that in the budesonide/formoterol group (1.02 liters). The total CAT score in the budesonide/formoterol group (348) was greater than that in the fluticasone/salmeterol group (308). The mean FEV_1/FVC ratio in the budesonide/formoterol group (17.4) was greater than in the fluticasone/salmeterol group (17.11). Fluticasone/salmeterol therapy was more effective than the budesonide/formoterol group in improving lung function (FEV_1/FVC ratio), while budesonide/formoterol was more effective than the

fluticasone/salmeterol group in improving clinical symptoms by CAT assessment (Table 2).

Mann-Whitney test on the effectiveness of the value of FEV_1/FVC ratio, it was known that value of P=0.007 was smaller than the probability (0.05.) Thus, it can be said that there was a significant difference between the use of fluticasone/salmeterol and budesonide/formoterol group (Table 2 and Figure 1).


Figure 1. Test of Differences in Effectiveness of FEV1/FVC Ratio with Ratio Scale

Table 1. Characteristics of Respondents

Characteristics		Group		P
		Budesonide/formoterol (n:20)	Fluticasone/salmeterol (n:18)	
Gender	Man	14	17	0.052
	Female	6	1	
Age (years)	40–50	1	0	
	51–60	7	4	
	61–70	8	11	0.526
	71–80	3	3	
	>80	1	0	
Job	Civil servant	0	1	
	General employees	3	1	0.441
	Self-employed	4	6	
	Other	13	10	
Smoking History	Quit smoking	7	13	
	Smoke	2	0	0.005*
	Did not smoke	11	5	
Drug Side Effects	Exist	0	0	1.000
	No	20	18	

Note= *) There was difference between the two groups

Table 2. Respondent Outcome Profile

Outcome		Group		P
		Budesonide/formoterol (n:20)	Fluticasone/salmeterol (n:18)	
Lung Function (Liters)	Total FEV1/FVC ratio	20.33	28.42	0.007
	Average FEV1/FVC ratio	1.02	1.58	
Clinical Symptoms	Total CAT	348	308	0.880
	Average	17.4	17.11	

Table 3. Cost Profile

Cost (in rupiah)		Group:		P
		Budesonide/formoterol (n:20)	**Fluticasone/salmeterol (n:18)**	
Direct medical cost (IDR)	Drug cost	154,424	142,737	
	Medical service	24,094	12,655	
	Physical service	40,000	40,000	0.069
	Laboratory service	58,212	58,212	
	Hospital service	25,000	25,000	
Average total cost (IDR)		301,730	278,604	

Table 4. Calculation Results of Cost-Effectiveness Analysis

CEA Calculation	Group:			
	Budesonide/formoterol (n:20)		**Fluticasone/salmeterol (n:18)**	
ACER lung function (IDR/Liter)	IDR	296,832 /Liter	IDR	176,465/Liter
ACER clinical symptoms	IDR	17,340/score	IDR	16,283/ score

There were 38 data that are all processed (no data is missing or missing), so the level of validity was 100%. The cross table that contained the relationship between drug therapy variables and CAT values. With ordinal data scale, fluticasone/salmeterol therapy (n:18) consisted of 5 people with mild group and 13 people with moderate-severe level. And budesonide/formoterol therapy (n:20) consisted of 6 people with mild group and 14 people with moderate-severe level. In the Pearson Chi-Square section, the value of P=0.880, it can be concluded that there was no significant relationship between the drug and the CAT value. This meaned that budesonide/formoterol and fluticasone/salmeterol have no correlation with CAT values (Figure 2).

Figure 2. Test of Differences in Effectiveness of Clinical Symtoms Ratio with Ordinal Scale

It was known that the costs for the two groups resulted P=0.069 explaining that there was an insignificant difference between the costs of budesonide/formoterol and fluticasone/salmeterol.

The costs used are direct medical costs, including drugs, medical service, physical service, laboratory service, and hospital service. Drug costs were the largest of the total costs. Average total cost in the budesonide/formoterol group (IDR. 301,730) was greater than in the fluticasone/salmeterol group (IDR. 278,604) (Table 3).

The ACER value of lung function between the fluticasone/salmeterol group (IDR. 176.465/Liter) was lower than that of budesonide/formoterol (IDR. 296.832/Liter). And the ACER clinical symptoms value between the fluticasone/salmeterol group (IDR. 16,283/score) was smaller than that of budesonide/formoterol (IDR. 17,340/score) (Table 4). It can be concluded that fluticasone/salmeterol was more cost-effective than budesonide/formoterol in improving lung function (FEV1/FVC ratio). Meanwhile, for clinical symptoms, fluticasone/salmeterol was a trade-off with budesonide/formoterol.

DISCUSSION

There were more male respondents than female (Table 1). COPD patients were more common in men. COPD was a condition in which the lung airways become inflamed and narrowed and the air sacs became damaged. It was a major cause of morbidity and mortality around the globe. Smoking cessation was particularly important in male COPD patients because of much higher proportion of smokers and are more likely to have cough and sputum.[20] These findings signify the importance of identifying and implementing gender-tailored

symptom management strategies to relieve symptom burden in COPD patients to enhance their quality of life.[21]

Age was often listed as a risk factor for COPD, but it was not clear whether healthy aging affects COPD or whether age reflects the cumulative amount of exposure over a lifetime. Patients with COPD at an early age or who had a strong relative history of COPD should be screened for risk for AAT deficiency, and if AAT concentrations are low, genetic (DNA) testing may be necessary.[9]

The highest age range was 61-70 years (Table 1), for elderly. COPD morbidity increases with age. Although the development of comorbid COPD can occur at a younger age. COPD was also more common at the age of >40 years than <40 years and was more common in males than females. Most of the increase in COPD mortality was due to the growing epidemic of smoking, decreased mortality from other common causes of death such as ischemic heart disease, infectious diseases.[22] In developing countries, deaths from COPD are also increasing, this was associated with an increase in the number of people who consume cigarettes. COPD had been considered as a disease affecting the elderly, with a preponderance in male smokers.[22,23]

In the budesonide/formoterol group, most did not smoke (55.00%). While in the fluticasone/salmeterol group, most of them had stopped smoking (72.22%). A person who quits smoking showed an improvement in lung function in the future. This was consistent with a previous study that increased FEV_1 in the first 6 and 12 weeks, in COPD patients after smoking cessation. In addition, both COPD patients and those with normal baseline respiratory function who quit smoking showed a significant increase in pulmonary transfer factor values for carbon monoxide from 6 weeks to 1 year of follow-up.[24] Side effects did not appear in all respondents. ICS together with LABA reduced the risk of exacerbations in COPD. ICS, however, do have side effects where an increased risk of pneumonia is probably the most clinically important one.[25]

COPD is diagnosed through spirometry, which can detect COPD even in people who do not yet have symptoms.[26] Currently, there is no cure for COPD, although available therapy can improve symptoms, quality of life, and prevent acute worsening of the disease. Pulmonary function in both groups of budesonide/formoterol and fluticasone/salmeterol by looking at the value of FEV1/FVC ratio obtained P=0.007 explained that there was a significant difference between lung function in the two groups. As for clinical symptoms, by looking at the CAT score obtained P=0.880, it explained that there was no significant difference between clinical symptoms and the CAT value between budesonide/formoterol and fluticasone/salmeterol. Fluticasone/salmeterol was more cost-effective than budesonide/formoterol in improving lung function (FEV_1/FVC ratio). Meanwhile, for clinical symptoms, fluticasone/salmeterol was a trade-off with budesonide/formoterol (Table 4).

The effectiveness parameter between lung warts (FEV_1) and symptoms has a low correlation. COPD symptoms exhibit high seasonal, weekly, and daily variability. Shortness of breath is a hallmark symptom of COPD and there is increasing evidence to suggest that the overall symptom burden (which may also include cough, sputum production, wheezing, and chest tightness) has a substantial adverse impact on health status, quality of life, and activities of daily living, and also contributes to increased anxiety and depression rates, increased risk of exacerbations, and poorer disease prognosis. Pulmonary function, on the other hand, shows circadian variation even in healthy individuals, so it is perhaps not surprising that many patients with COPD experience variations in their symptoms throughout the day, with symptoms being most severe in the morning and evening. There was a statistically significant correlation between total lung capacity and COPD severity.[27]

In this study, only direct medical costs were involved, according to the hospital's perspective. COPD results in substantial costs to the health system, particularly in relation to its moderate to severe stage and its associated exacerbations and complications. It is important to strengthen the health

system with a health monitoring, evaluation and education model that allows these patients to remain stable to avoid decompensation and subsequent hospitalization. In the case of very common chronic diseases, it is important to measure the social and financial magnitude of the disease in all areas (direct and indirect costs, health and non-medical costs, labor losses and intangible costs).[10]

It is important to note that cost variability in reported outcomes is largely a consequence of methodological divergences and research objectives impacting the type of cost in the way resources are identified, measured, valued, and consumed by COPD patients in various studies.[10]

ACER of lung function between the fluticasone/salmeterol group was lower than that of budesonide/formoterol, and the ACER of clinical symptoms between the fluticasone/salmeterol group was smaller than that of budesonide/formoterol. ACER represents the average cost required to obtain clinical results. Based on previous research by Tamminen et al. to explore the cost-effectiveness of budesonide/formoterol maintenance and reliever therapy as compared to fixed combination therapies (budesonide/formoterol and salmeterol/fluticasone) with terbutaline as needed in the treatment of asthma in Finland. Budesonide/formoterol maintenance and reliever therapy may be considered in the treatment of moderate-to-severe asthma instead of conventional treatment with combination products in view of its good clinical efficacy and a high probability of cost-effectiveness in the Finnish setting.[28]

While other studies that tested the effectiveness, by Robert et al, of the 6770 patients (3385 budesonide/formoterol and 3385 fluticasone/salmeterol), fewer budesonide/formoterol patients had claims for short-acting beta agonists (SABA) (34.7% vs 39.5%; $P<0.001$) and ipratropium (7.8% vs 9.8%, $P<0.005$) than fluticasone/salmeterol patients, but no substantial differences were seen in other clinical outcomes including tiotropium or nebulized SABA claims, COPD-related outpatient visits, or exacerbation events. There were no significant differences in total COPD-related medical costs in the 6-month period after initiation of combination therapy.[29]

LIMITATION

The limitations of this study were the presence of several factors that can affect pulmonary function scores and clinical symptoms other than inhaler therapy used, such as the severity of COPD, and other therapies used for COPD or other therapies.

CONCLUSION

Fluticasone/salmeterol therapy was more cost-effective than budesonide/formoterol in improving lung function in FEV_1/FVC ratio. And fluticasone/salmeterol was a tradeoff with budesonide/formoterol in clinical symptoms in CAT score. No drug side effects were found between fluticasone/salmeterol and budesonide/formoterol.

REFFERENCE

1. Yawn BP, Mintz ML, Doherty DE. GOLD in practice: Chronic obstructive pulmonary disease treatment and management in the primary care setting. Int J Chron Obstruct Pulmon Dis. 2021;16:289–99.
2. Iglesias JR, Díez-Manglano J, García FL, Peromingo JAD, Almagro P, Aguilar JMV. Management of the COPD patient with comorbidities: An experts recommendation document. Int J Chron Obstruct Pulmon Dis. 2020;15:1015.
3. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557–82.
4. Jardim JR, Nascimento OA. The importance of inhaler adherence to prevent COPD exacerbations. Medical Sciences. 2019;7(4):54.
5. Shetty N, Cipolla D, Park H, Zhou QT. Physical stability of dry powder inhaler formulations. Expert Opin Drug Deliv. 2020;17(1):77–96.

6. Ozdemir T, Kilic H, Demirci NY, Ozdilekcan C, Bektemur G, Turkkani MH, et al. Five-year trends in direct costs of chronic obstructive pulmonary disease in turkey: COPDTURKEY-3. Turk Thorac J. 2021;22(5):393–8.

7. Alaydrus S. Analisis biaya pengobatan penyakit paru obstruktif kronik pasien rawat inap rumah sakit umum daerah kabupaten sukoharjo. Jurnal Ilmiah Farmasi Farmasyifa. 2020;3(1):51–61.

8. Voorham J, Corradi M, Papi A, Vogelmeier CF, Singh D, Fabbri LM, et al. Comparative effectiveness of triple therapy versus dual bronchodilation in COPD. ERJ Open Res. 2019;5(3):00106–2019.

9. Choi JY, Rhee CK. Diagnosis and treatment of early chronic obstructive lung disease (COPD). J Clin Med. 2020;9(11):1–20.

10. Gutiérrez Villegas C, Paz-Zulueta M, Herrero-Montes M, Parás-Bravo P, Madrazo Pérez M. Cost analysis of chronic obstructive pulmonary disease (COPD): A systematic review. Health Econ Rev. 2021;11(1):31.

11. Franklin M, Lomas J, Richardson G. Conducting value for money analyses for non-randomised interventional studies including service evaluations: An educational review with recommendations. Pharmacoeconomics. 2020;38(7):665–81.

12. Tonin FS, Aznar-Lou I, Pontinha VM, Pontarolo R, Fernandez-Llimos F. Principles of pharmacoeconomic analysis: The case of pharmacist-led interventions. Pharm Pract (Granada). 2021;19(1):1–10.

13. Qu S, You X, Liu T, Wang L, Yin Z, Liu Y, et al. Cost-effectiveness analysis of COPD screening programs in primary care for high-risk patients in china. NPJ Prim Care Respir Med. 2021;31(1):28.

14. Patel AR, Patel AR, Singh S, Singh S, Khawaja I. Global initiative for chronic obstructive lung disease: The changes made. Cureus. 2019;11(6):e4985.

15. Fazleen A, Wilkinson T. Early COPD: Current evidence for diagnosis and management. Ther Adv Respir Dis. 2020;14:1753466620942128.

16. Stridsman C, Svensson M, Johansson Strandkvist V, Hedman L, Backman H, Lindberg A. The COPD assessment test (CAT) can screen for fatigue among patients with COPD. Ther Adv Respir Dis. 2018;12:1753466618787380.

17. Sim YS, Lee JH, Lee WY, Suh DI, Oh YM, Yoon JS, et al. Spirometry and bronchodilator test. Tuberc Respir Dis (Seoul). 2017;80(2):105–12.

18. Gold WM, Koth LL. Pulmonary function testing. In: Murray and Nadel's Textbook of Respiratory Medicine. Elsevier; 2016. p. 407–35.

19. Hoesterey D, Das N, Janssens W, Buhr RG, Martinez FJ, Cooper CB, et al. Spirometric indices of early airflow impairment in individuals at risk of developing COPD: Spirometry beyond FEV1/FVC. Respir Med. 2019;156:58–68.

20. Lorensia A, Pratama AM, Hersandio R. Knowledge and attitudes on smoking cessation of e-cigarettes: A mixed-methods study of pharmacy students in surabaya, indonesia. J Prev Med Hyg. 2022;62(4):E918–25.

21. Zhang H, Wu F, Yi H, Xu D, Jiang N, Li Y, et al. Gender differences in chronic obstructive pulmonary disease symptom clusters. Int J Chron Obstruct Pulmon Dis. 2021;16:1101–7.

22. Divo MJ, Celli BR, Poblador-Plou B, Calderón-Larrañaga A, de-Torres JP, Gimeno-Feliu LA, et al. Chronic obstructive pulmonary disease (COPD) as a disease of early aging: Evidence from the EpiChron Cohort. PLoS One. 2018;13(2):e0193143.

23. Moryson W, Stawinska-Witoszynska B. Premature mortality due to chronic obstructive pulmonary disease (COPD) in Poland. Medicina (B Aires). 2021;57(2):1–7.

24. Gülşen A. Pulmonary function changes in chronic obstructive pulmonary disease patients according to smoking status. Turk Thorac J. 2020;21(2):80–6.

25. Janson C. Treatment with inhaled corticosteroids in chronic obstructive pulmonary disease. J Thorac Dis. 2020;12(4):1561–9.

26. Lorensia A, Muntu CM, Suryadinata RV, Septiani R. Effect of lung function disorders and physical

activity on smoking and non-smoking students. J Prev Med Hyg. 2021;62(1):E89–96.

27. Miravitlles M, Ribera A. Understanding the impact of symptoms on the burden of COPD. Respir Res. 2017;18(1):1–11.

28. Tamminen K, Laine J, Soini E, Martikainen J, Kankaanranta H. Cost-effectiveness analysis of budesonide/formoterol maintenance and reliever therapy versus fixed combination treatments for asthma in Finland*. Curr Med Res Opin. 2008;24(12):3453–61.

29. Roberts M, Mapel D, Petersen H, Blanchette C, Ramachandran S. Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management. J Med Econ. 2011;14(6):769–76.